Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.
Publication
, Conference
Petrylak, DP; Flaig, TW; Mar, N; Gourdin, TS; Srinivas, S; Rosenberg, JE; Guseva, M; Yu, Y; Narayanan, S; Hoimes, CJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
2022
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Petrylak, D. P., Flaig, T. W., Mar, N., Gourdin, T. S., Srinivas, S., Rosenberg, J. E., … Hoimes, C. J. (2022). Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).
Petrylak, Daniel P., Thomas W. Flaig, Nataliya Mar, Theodore Stewart Gourdin, Sandy Srinivas, Jonathan E. Rosenberg, Maria Guseva, Yao Yu, Sujata Narayanan, and Christopher J. Hoimes. “Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.
Petrylak DP, Flaig TW, Mar N, Gourdin TS, Srinivas S, Rosenberg JE, et al. Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible. In: JOURNAL OF CLINICAL ONCOLOGY. 2022.
Petrylak, Daniel P., et al. “Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.
Petrylak DP, Flaig TW, Mar N, Gourdin TS, Srinivas S, Rosenberg JE, Guseva M, Yu Y, Narayanan S, Hoimes CJ. Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible. JOURNAL OF CLINICAL ONCOLOGY. 2022.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2022
Volume
40
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences